Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454881 | 0.87 | CA1 (0.49) | CA1CA2CA9NR1I2ATM | |
| SCHEMBL22751141 | 0.84 | CA1 (0.49) | CA1CA2CA9ATMHSD11B1 | |
| SCHEMBL4517030 | 0.84 | CA1 (0.49) | CA1CA2CA9ATMHSD11B1 | |
| SCHEMBL15927488 | 0.84 | MRGPRX4 (0.42) | CA1CA2CA9ALDH1A1L3MBTL1 | |
| SCHEMBL29365046 | 0.82 | CA1 (0.50) | CA1CA2CA9ATMHSD11B1 | |
| SCHEMBL1772862 | 0.82 | CA1 (0.50) | CA1CA2CA9ATMHSD11B1 | |
| SCHEMBL2456740 | 0.81 | CA1 (0.57) | CA1CA2CA9NR1I2ATM | |
| SCHEMBL495940 | 0.81 | CA1 (0.49) | CA1CA2CA9ATMHSD11B1 | |
| SCHEMBL23619103 | 0.80 | CA1 (0.45) | CA1CA2CA9ATMHSD11B1 | |
| SCHEMBL4513577 | 0.80 | CA1 (0.45) | CA1CA2CA9ATMHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101646648-B | Tert-butylphenyl sulfonate compound, nonaqueous electrolyte solution for lithium secondary battery using same, and lithium secondary battery using same | UBE IND JP | 2014-07-16 | — | — | CN | disclosed |
| US-20140011097-A1 | TERT-BUTYLPHENYL SULFONATE COMPOUND, NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY USING THE SAME, AND LITHIUM SECONDARY BATTERY USING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
| US-8546599-B2 | Tert-butylphenyl sulfonate compound, nonaqueous electrolyte solution for lithium secondary battery using the same, and lithium secondary battery using the same | UBE INDUSTRIES, LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20100055576-A1 | tert-BUTYLPHENYL SULFONATE COMPOUND, NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY USING THE SAME, AND LITHIUM SECONDARY BATTERY USING THE SAME | MU IONIC SOLUTIONS CORPORATION (JP) | 2010-03-04 | — | — | US | disclosed |
| CN-101646648-A | Tert-butylphenyl sulfonate compound, nonaqueous electrolyte solution for lithium secondary battery using same, and lithium secondary battery using same | UBE IND JP | 2010-02-10 | — | — | CN | disclosed |
| EP-2133327-A1 | tert-BUTYLPHENYL SULFONATE COMPOUND, NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY USING THE SAME, AND LITHIUM SECONDARY BATTERY USING THE SAME | Ube Industries, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055576-A1 | tert-BUTYLPHENYL SULFONATE COMPOUND, NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY USING THE SAME, AND LITHIUM SECONDARY BATTERY USING THE SAME | TERT, TST, TES | CA1 3264/4885CA2 2362/4885CA9 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.